World Health Organization Issues Alert Over Acute Lack of Weight-Loss Injections

Fewer than one in 10 individuals who could benefit from weight-loss injections including Wegovy have access to them, caution the World Health Organization as it releases its first guidance on the medications.

With over a billion individuals worldwide now living with obesity, it is urging broader and more equitable access to GLP-1 medication.

Per estimates, more than two billion will be obese by 2030 if no action is taken.

"The new guidance affirms that excess weight is a lifelong illness that can be addressed with comprehensive and ongoing care," said WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and logistical bottlenecks are major barriers to broad access to the injections that can help people shift considerable weight, says the agency.

Skinny Jab Scarcity

Even in the current most favorable scenario, the supply of such drugs might only reach about 100 million people – fewer than 10% of eligible patients, per the health organization.

The guideline encourages nations and manufacturers to widen availability, by strategies like patent sharing.

Exclusive production rights on the active ingredient – the primary component of a leading brand – is scheduled to end in multiple countries in 2026.

The Way Obesity Jabs Function

GLP-1 drugs replicate a natural hormone to slow digestion, reduce hunger and enhance feelings of fullness so users eat less.

People commonly see weight reduction in the initial weeks of commencing the weekly injections.

Studies indicates patients may see weight return a year later of halting the treatment, because their usual food cravings come back.

Being above a healthy weight raises your chance for experiencing health problems, like type 2 diabetes, heart disease, stroke, and certain cancers.

Obesity affects individuals in all nations and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.